Anatara Lifesciences

Commercialising innovative, evidence-based therapies for gastrointestinal health where there is significant unmet need.
Anatara Lifesciences
Operating

Anatara Lifesciences (ASX: ANR) is developing and commercialising innovative, evidence-based products for gastrointestinal health where there is significant unmet need. Anatara is a specialist life sciences company with expertise in developing products for animal and human health. We are currently focused on building a pipeline of evidence-based, over-the-counter gastrointestinal health products, through in-house development and in-licencing and distribution opportunities. Underlying this product development program is our commitment to delivering real outcomes for patients and strong value for our shareholders. Human Applications Our initial Gastrointestinal ReProgramming (GaRP) over-the-counter medicine is focused on addressing the chronic symptoms associated with irritable bowel syndrome (IBS) and the inflammatory bowel diseases (IBD). 11% of the global population is affected by IBS and there are 5 million IBD sufferers worldwide. GaRP has been designed as an everyday option for patients to manage ongoing chronic symptoms as well as minimise episodic flare ups. Animal Applications Anatara’s foundations are built on strong and successful science. Anatara's first product, Detach®, is a non-antibiotic approach to aid in the control of diarrhoeal disease (known as scour in livestock) in piglets. Scour in piglets is an expensive, debilitating and in some cases, life-threatening condition. Detach® is safe and effective. It is the result of more than 20 years of scientific research and development. Anatara is evaluating commercialisation opportunities for Detach® including options for launch in Australia, regulatory approval of this product in overseas markets, development of this product for species other than piglets and global or regional licensing of Detach®. About Us Backed by a well credentialed Board and Management team, and world-leading scientific collaborators, Anatara is uniquely positioned to fulfill a significant unmet medical need in gut health.

Videos
Investors
Investor

Brisbane Angels

Images
Taken on 2020-09
Blog Posts
20th September, 2023
1 Aug 2023

IBS clinical trial Stage 1 patients finalised

20th September, 2023
14 Aug 2023

$923,235 in R&D tax incentive received

20th September, 2023
24 Aug 2023

Appendix 4E & Audited Financial Statements 30 June 2023

10th September, 2023
31 Aug 2023

IBS clinical trial Stage 1 patients finalised

20th May, 2022
Expanded eligibility criteria for IBS and psychological functioning trials

20 May 2022: Yvette Ogilvie, Markets Reporter Link to The Market Herald Anatara Lifesciences (ANR) h...

10th September, 2021
Meet the CEO of Anatara

9 SEPTEMBER 2021 Hosted by Market Eye, CEO Steve Lydeamore provides an update on the Company’s lates...

14th March, 2021
NUTRAingredients “IBS and mental health”

IBS and mental health: Anatara Lifesciences to trial supplement that targets colon and small intesti...

21st October, 2020
Interview with Sonia Madigan – The Deal Room

Anatara Lifesciences Ltd (ASX:ANR) CEO Steve Lydeamore was recently interviewed by Sonia Madigan – T...

14th September, 2020
Anatara Lifesciences Limited ASX Small & Mid Cap Conference

ASX:ANR 8 September 2020 “Anatara Lifesciences Ltd (ASX:ANR) chief executive officer Steve Lydeamore...

8th September, 2020
Anatara Lifesciences with Proactive at ASX Small and Mid-Cap Conference

Proactive 8 September 2020 By mailto:[email protected] “Anatara Lifesciences Ltd (...

 Location
Melbourne
 People
No information available.
 Tags
#health
#health tech
#life sciences
#sci tech
#science
 Feedback